Novo Nordisk's reimbursement appeal goes unheard, Sanofi insulin deemed equivalent

The Danish Medicines Agency's Reimbursement Committee has decided to ignore Novo Nordisk's pleas to leave the company's general reimbursement scheme untouched. Instead, it recommends other fast-acting insulins for new patients.
A trip to the pharmacy for users of Novo Nordisk's Fiasp could become more expense going forward. The Danish Medicines Agency's Reimbursement Committee has recommended a adjusting the fast-acting insulin's reimbursement scheme for the worse.
A trip to the pharmacy for users of Novo Nordisk's Fiasp could become more expense going forward. The Danish Medicines Agency's Reimbursement Committee has recommended a adjusting the fast-acting insulin's reimbursement scheme for the worse.
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen

The Danish Medicines Agency has received the Reimbursement Committee's final recommendation for a revision pertaining to the reimbursement scheme for insulin products – and it doesn't bode well for Novo Nordisk.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading